louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06623448: Nursing Students and Artificial Intelligence
Official title: Nursing Students&Amp;#39; Readiness for Medical Artificial Intelligence and Artificial Intelligence Anxiety: A Mixed Method Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nursing Students
Lead sponsor: Necmettin Erbakan University
Sponsor class: OTHER
First posted: 2024-10-02
Enrollment: 358
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 977

Brief summary: The aim of this observational study is to examine nursing students\&#39; readiness for medical AI and their anxiety about AI using a mixed method.

The main question it aims to answer is:

Nursing students\&#39;;

1. What is their level of awareness of medical artificial intelligence?
2. What is their level of artificial intelligence anxiety?
3. Is there a relationship between artificial intelligence awareness and anxiety levels?
4. What are the opinions of those who have artificial intelligence anxiety about artificial intelligence?

In the 1st stage, nursing students answered the related survey questions online. In the 2nd stage, qualitative interviews were conducted with those with high AI anxiety scores and evaluated.


Eligibility criteria: Inclusion Criteria:

To be a student of Necmettin Erbakan University Faculty of Nursing To be a student of Necmettin Erbakan University Kamil Akkanat Faculty of Health Sciences, Department of Nursing

Exclusion Criteria:

Students who did not consent to participate were excluded

Primary outcomes:
measure: Artificial intelligence awareness level and artificial intelligence anxiety leve
timeFrame: Until the end of August 2025
Secondary outcomes:
measure: Students&#39; views on artificial intelligence
timeFrame: 5th September
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: Necmettin Erbakan University
Study officials:
References:
Clinical trial NCT02914548: Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
Official title: A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Assess the Efficacy and Safety of 0.3% and 1% OPA-15406 Ointments in Patients With Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atopic Dermatitis
Lead sponsor: Otsuka Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-09-26
Enrollment: 200
Sex: ALL
Minimum age (years): 15
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka

Exclusion Criteria:

* Subjects who have an atopic dermatitis or contact dermatitis flare-up defined as a sudden intensification of atopic dermatitis.
* Subjects who have an active viral skin infection.
* Subjects with a current or history of malignancy.

Primary outcomes:
measure: Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4
timeFrame: At Week 4
Secondary outcomes:
measure: Change From Baseline in Eczema Area and Severity Index (EASI) Score
timeFrame: Baseline, Week 4
measure: Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score
timeFrame: Baseline, Week 4
measure: Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score
timeFrame: Baseline, Hour 156
measure: Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score
timeFrame: Baseline, Week 4
measure: Change From Baseline in Percentage Affected Body Surface Area
timeFrame: Baseline, Week 4
measure: Mean (SD) OPA-15406 Plasma Trough Concentrations
timeFrame: Week1, Week4, Week8
measure: Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA
timeFrame: Week1, Week4, Week8
measure: OPA-15406 Plasma PK Parameters, Cmax
timeFrame: Day 1 and Week 4
measure: OPA-15406 Plasma PK Parameters, AUC8h
timeFrame: Day 1 and Week 4
Other outcomes:
Locations:
city: Hokkaido Region
country: Japan
city: Kanto Region
country: Japan
city: Kiniki Region
country: Japan
Study officials:
affiliation: Otsuka Pharmaceutical Co., Ltd.
name: Hiroaki Ono, Mr
role: STUDY_DIRECTOR
References:
Clinical trial NCT06762457: A First-in-Human Single and Multiple Ascending Dose Study of MT-501
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of MT-501 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: MT-501
Phase 1
Lead sponsor: Mirador Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2025-01-07
Enrollment: 96
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of MT-501 in Healthy Adults.

Detailed description: This study is the first administration of MT-501 in healthy volunteers (HV). The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of up to 8 days of MT-501 in HV. The safety, tolerability, PK, and PD data obtained from this study will inform further development of MT-501.

Eligibility criteria: Inclusion Criteria:

1. Male or female (of non-childbearing potential only) between 19 and 55 years of age inclusive, at the time of signing informed consent.
2. Females must be of non-childbearing potential and must have undergone sterilization procedures, and have official documentation, at least 6 months prior to the first dose.
3. Male subjects must use highly effective forms of contraception during sexual intercourse with female partners of childbearing potential. A non-vasectomized, male subject must agree to use a condom with a chemical barrier method.
4. Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the first dose of drug.
5. Good general health.
6. Able to provide written informed consent and understand and comply with the requirements of the study.

Exclusion Criteria:

1. History or presence of any clinically significant organ system disease.
2. Abnormal laboratory assessments, physical exam of ECG outside the normal range that is judged by the Investigator to be clinically significant.
3. History of alcohol or drug abuse within the past 24 months.
4. Current use or history of regular tobacco, or nicotine-containing products within 3 months prior to screening.
5. Administration or use of any investigational drug or device within 30 days preceding the first does of study drug administration.

Primary outcomes:
measure: Primary Outcome Measure: Number of Subjects with non-SAEs and SAES
timeFrame: Up to 14 days post dose
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Mirador Clinical Department
state: California
Study officials:
References:
Clinical trial NCT03265457: The Endothelial Count in Pxf
Official title: The Corneal Endothelial Cell Count in Eyes With Pseudoexfoliation Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pseudoexfoliation Syndrome
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-08-29
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with pseudoexfoliation syndrome

Brief summary: Pseudoexfoliation Syndrome Is a common disorder in Egypt. IT is one of the common causes of coexisting cataract and glaucoma. It may be associated with a less than normal endothelial count.

Detailed description: The corneal Endothelium is essential for the maintenance of normal corneal hydration, thickness, and transparency.

In patients with pseudoexfoliation syndrome , quantitative and qualitative morphological changes of the corneal endothelium have been demonstrated in specular and electron microscopic studies.

Specular microscopy is a non-invasive technique to access the structure and function of the corneal endothelium.

Our research question is to study Endothelial cell count in patients with pseudoexfoliation syndrome \& compare it to age matched group.

Eligibility criteria: Inclusion Criteria:

* Patients with pseudoexfoliation syndrome

Exclusion Criteria:

* Patients with previous intra ocular surgeries.
* Patients with uveitis
* Patients with fuck's endothelial dystrophy

Primary outcomes:
measure: Comparison between endothelial cell count in patients with Pseudoexfoliation syndrome and age matched controls.
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Miyake K, Matsuda M, Inaba M. Corneal endothelial changes in pseudoexfoliation syndrome. Am J Ophthalmol. 1989 Jul 15;108(1):49-52. doi: 10.1016/s0002-9394(14)73259-3.
Clinical trial NCT05562557: A Regional Partnership to Improve Outcomes Through Fatherhood Engagement
Official title: A Regional Partnership for New York City to Improve Well-Being and Child Welfare Outcomes Among Families at Risk of Substance Misuse Through Fatherhood Engagement
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Substance Use
Child Abuse
Child Neglect
Fathers
Father-Child Relations
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
Collaborators: name: Albert Einstein College of Medicine
First posted: 2022-09-30
Enrollment: 240
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Montefiore will engage fathers in families at risk of substance misuse in the Bronx and neighboring communities. Families will be referred from Bronx and neighboring community-based child welfare systems, substance use disorder (SUD) treatment providers, and medical providers if identified at risk of substance use concerns and will be randomly assigned to receive services as usual as part of the comparison group, or to receive enhanced services as part of the program group.

Enhanced services include: (1) Motivational Enhancement; (2) referral to Healthy, Empowered, Resilient, and Open (HERO) Dads fatherhood engagement program; (3) Contingency Management; and (4) Case Management.


Eligibility criteria: Inclusion Criteria:

* (i) is a custodial or non-custodial father,
* (ii) who has at least one child under the age of 18,
* (iii) someone in the family is identified as at-risk for substance use

Exclusion Criteria:

* The placement of all children in the family in foster care

Primary outcomes:
measure: Child well-being, as measured by: Child Behavior Checklist
timeFrame: Baseline
measure: Child well-being, as measured by: Child Behavior Checklist
timeFrame: Follow Up (6-months after Baseline)
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
Study officials:
affiliation: Montefiore Medical Center
name: Scott Wetzler, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02588157: Effect of Cricoid Pressure on Macintosh, McGrath X-Blade and Glidescope Videolaryngoscopes in Rapid Sequence Induction Intubation
Official title: Videolaryngoscopes for Rapid Sequence Intubation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Rapid Sequence Induction Intubation
Keywords: Rapid sequence induction intubation
McGrath X-Blade
Glidescope
Macintosh
Lead sponsor: Kocaeli University
Sponsor class: OTHER
First posted: 2015-10-27
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Non- Fasted patients need rapid sequence intubation. The investigators aimed to compare the intubation times of Macintosh , and McGrath X-Blade or Glidescope in these Ascenario.

Detailed description: The investigators fecidedir to enroll the ASA I-II 120 patients and divided them into three groups ( Macintosh / McGarth X-Blade / Glidescope). The investigators recorded the patients' airway data and demographic variables. All patients were premeditated with midazolam. Standard monitoring including electrocardiogram, non invasive blood pressure, pulse oximetry, heart rate were recorded before induction , after induction, after the device insertion and every 1 minutes after intubation. Cormac-Lehan grades with these video laryngoscope were recorded also. We recorded the optimization maneuvers ( like handling force, reinserting, cricoid pressure). Bloodstaining on the devices after removal were recorded as mucosal damage. Teeth, tongue, lip damage were also recorded. Sore throat, bronchospasm, wheezing were recored at recovery unit.

Eligibility criteria: Inclusion Criteria:

* ASA I-II
* BMI\< 30
* 18-65 years of age

Exclusion Criteria:

* known difficult airway
* BMI \> 30
* \< 18 years of age
* \> 65 years of age
* known respiratory tract infection in 10 days
* pregnant

Primary outcomes:
measure: cormack lehane grade with cricoid pressure
timeFrame: 1 minutes
measure: intubation time
timeFrame: 2 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli University
Study officials:
References:
Clinical trial NCT03070457: Safety of an Early Discharge Protocol After Sleeve Gastrectomy
Official title: Safety of an Early Discharge Protocol After Sleeve Gastrectomy. Randomised Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Morbid Obesity
Sleeve Gastrectomy
Early Discharge
Safety Issues
Keywords: bariatric surgery
sleeve gastrectomy
eras
Lead sponsor: Hospital Universitari de Bellvitge
Sponsor class: OTHER
First posted: 2017-03-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate the safety and efficacy of an early discharge protocol (23 hours, overnight stay) after scheduled sleeve gastrectomy.

Detailed description: This study aims to demonstrate that a shorter hospital stay after sleeve gastrectomy is as safe and useful as conventional protocol with 48-36 hours of stay. We consider that an adequate patient information and support will facilitate this shorter stay

Eligibility criteria: Inclusion Criteria:

* Patients eligible for Sleeve gastrectomy
* BMI 35 to 50
* ASA I to III
* Conventional address close to our Hospital
* Laparoscopic surgery
* Accompanying person after discharge
* Availability for a smart phone

Exclusion Criteria:

* ASA IV
* Revisional Surgery
* Conversion to laparotomy
* ICU Admission after surgery
* Insulin dependent Diabetes Mellitus
* Surgery finishing after 3 pm

Primary outcomes:
measure: Readmissions rate
timeFrame: 1 month
Secondary outcomes:
measure: Morbidity rate
timeFrame: 1 month
measure: Chronogram for complications after surgery
timeFrame: 1 month
measure: Quality of life
timeFrame: 1 month
measure: Patients agreement to the protocol
timeFrame: 1 month
Other outcomes:
Locations:
city: L'Hospitalet de Llobregat
country: Spain
facility: Hospital Universitari de Bellvitge
state: Barcelona
Study officials:
References:
Clinical trial NCT06303557: Effect of ESPB on Intraoperative Remifentanil Consumption
Official title: Effect of ESPB on Intraoperative Remifentanil Consumption in Lumbar Spine Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lumbar Spine Surgery
Erector Spinae Plane Block
Remifentanil Consumption
Lead sponsor: Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
Sponsor class: OTHER
First posted: 2024-03-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In recent years, regional anesthesia techniques have also been frequently applied to patients for pain relief. Erector spinae plane block (ESPB), is among the regional anesthesia techniques frequently used in lumbar spine surgery.

General anesthesia (GA) is the main method of anesthesia for lumbar spine surgery. However, GA can only inhibit the projection system of the cortical limbic system or hypothalamic cortex. GA cannot completely block the transmission of peripheral noxious stimulus to the central nervous system and cannot effectively inhibit the intraoperative stress response. With the addition of peripheral blocks such as ESPB, lower remifentanil consumption, and more stable hemodynamics are expected by providing preemptive analgesia in patients.

As a result of all these; it was aimed to compare the intraoperative remifentanil consumption of patients who underwent preoperative ESPB in patients who will undergo lumbar spine surgery resection under GA with those who underwent postoperative ESPB.


Eligibility criteria: Inclusion Criteria:

* 18 to 65 years old
* American Society of Anesthesiologists (ASA) physical status I-II-III
* Body mass index 18 to 40 kg/m2
* Elective lumbar disc herniation surgery

Exclusion Criteria:

* Patient refusing the procedure
* Patients who have previously undergone spinal surgery
* Chronic opioid or analgesic use
* Patients who will operate under emergency conditions
* Patients who will not undergo lumbar disc herniation surgery

Primary outcomes:
measure: Intraoperative remifentanil consumption
timeFrame: During the intraoperative period
Secondary outcomes:
measure: Mean arterial pressure
timeFrame: Perioperative period
measure: Heart rate
timeFrame: Perioperative period
measure: Pain scores
timeFrame: First 24 hours after surgery
Other outcomes:
Locations:
city: Yenimahalle
country: Turkey
facility: Ankara Etlik City Hospital
state: Ankara
Study officials:
References:
Clinical trial NCT02462057: Testing Different Messaging Approaches to Increase Activation of a HealthyFood Benefit in Adults With Diabetes
Official title: Testing the Effectiveness of Different Messaging Approaches to Increase Activation of a HealthyFood Benefit Amongst Individuals With Diabetes: A Randomised, Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Diet
Incentives
Messaging
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: Discovery Health
First posted: 2015-06-03
Enrollment: 5467
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The Vitality HealthyFood benefit is a three-tiered incentive program designed to encourage healthier food choices amongst members of Discovery Health's Vitality program. Once enrolled in the benefit, participating members can receive 10%, 15%, or 25% cash-back on the healthy foods they purchase at selected grocers. And, while overall enrollment in the program is high, there is particular interest in increasing enrollment in the benefit amongst Vitality members with diabetes. One presumed barrier to enrollment in the benefit amongst members with diabetes is a misperception of the particular relevance of the benefit and healthier food choices for their personal health. Improved messaging regarding the HealthyFood benefit and its particular salience for individuals with diabetes may be an effective means of increasing activation of the benefit in this population. The proposed study will be a collaboration between Discovery Health/Vitality and researchers at the Perelman School of Medicine at the University of Pennsylvania. In the proposed RCT, Vitality members with diabetes will be randomised to different types of messages regarding the HealthyFood benefit. The investigators will then compare the effectiveness of these different messaging strategies at increasing activation of the HealthyFood benefit amongst Vitality members with diabetes.


Eligibility criteria: Inclusion Criteria:

1. Adults over age 18
2. Vitality health members who have not yet enrolled in the Vitality HealthyFood benefit
3. Diagnosis of type 2 diabetes (based on registration for chronic benefits for type 2 diabetes)
4. Have registered on to Discovery Health/Vitality website in the past (marker of Internet access and availability of email address)

Exclusion Criteria:

* Anyone who does not meet above criteria

Primary outcomes:
measure: Enrollment in 10% Level of Benefit
timeFrame: One month from initial emailed messages
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Gopalan A, Paramanund J, Shaw PA, Patel D, Friedman J, Brophy C, Buttenheim AM, Troxel AB, Asch DA, Volpp KG. Randomised controlled trial of alternative messages to increase enrolment in a healthy food programme among individuals with diabetes. BMJ Open. 2016 Nov 30;6(11):e012009. doi: 10.1136/bmjopen-2016-012009.